What people seeking or managing obesity care are experiencing when GLP-1 and other anti-obesity treatments meet insurance exclusions, prior authorization, recurring out-of-pocket costs, and difficult choices about whether care can continue.
Audience: People living with Obesity
Countries: USA, UK, Canada, Italy, France
SGID: 8916068
-Hero findings
– Quick Read — Key Findings
The full report follows coverage, prior authorization, monthly spending, treatment interruptions, and the search for lower-cost alternatives.
WHO now describes obesity as a chronic, relapsing disease and in December 2025 issued its first global guideline on GLP-1 therapies for obesity in adults. The guidance also highlights cost, health-system preparedness, and equity as reasons recommendations must be implemented carefully.
Those system questions are visible in the MDForLives survey. Respondents describe uncertainty about coverage, prior-authorization barriers, out-of-pocket spending, treatment interruptions, and what they would do if a recommended medicine were not reimbursed.
Context: World Health Organization, Obesity and overweight and the 2025 guideline on GLP-1 therapies for obesity in adults.
MDForLives Research Interpretation
30.1% are unsure whether their coverage includes prescription anti-obesity medicines, while 28.0% say these medicines are explicitly excluded.
What the pattern means: Uncertainty is as common as explicit exclusion. That means the access burden includes information friction before the affordability calculation even begins.
17.0% have interrupted recommended treatment multiple times because of cost and another 19.3% have done so once or twice.
What the pattern means: Affordability is not an abstract concern. It is already changing treatment behavior for a substantial share of respondents.
29.5% name insurance denial or complex prior approval as the single biggest hurdle they have faced seeking medical obesity care.
What the pattern means: Access friction is concentrated in the approval pathway more than the point-of-sale copay alone.
39.8% would look for lower-cost alternative, compounded, or imported options if the prescribed anti-obesity medication were not reimbursed.
22.7% say obesity care requires careful monthly budgeting and 11.4% say they reduce spending on essentials to afford care.
What the pattern means: Most respondents describe low or no impact, but the financially vulnerable subgroup is large enough to matter in any long-term care model.
25.3% prioritize lower treatment prices, while 24.1% choose mandated medicine coverage and another 24.1% choose coverage of dietitian and behavioral care.
What the pattern means: The response distribution is unusually balanced. Patients are describing an access problem distributed across price, benefits, and the wider care team.
For people trying to manage obesity, the financial question often arrives after the clinical decision: what is covered, what must be paid every month, how long an approval lasts, and what happens if the cost suddenly changes. The survey shows why affordability should be discussed as part of treatment planning from the beginning, not after a patient has already started and then has to decide whether they can continue.
Ask about the recurring monthly cost, not only the first prescription, and include visits, tests, nutrition, behavioral support, and other services in the estimate.
Understand prior-authorization renewal, appeal routes, covered alternatives, and whom to contact before treatment is interrupted.
Discuss alternatives with the prescribing clinician and use regulated supply channels rather than assuming cheaper products are clinically equivalent.
You have read the summary
Direct answers to common questions around this topic.
Direct answers to the questions healthcare professionals are most likely to ask about these findings.
